Studies also in VEGFA-overexpressed human tumors and mouse tumor models revealed that apatinib plus PD-1/PD-L1 blockade therapy could alleviate hyperangiogenesis and hypoxia in TME and also alter the immunosuppressive TME into an immunostimulatory microenvironment [109]. This evidence concerns the gene PDCD1 and neoplasm.